Why Hims & Hers Stock Sank This Week
Hims & Hers posted record revenue this quarter.
It is still selling patented weight loss drugs on its platform and is now getting sued by the pharmaceutical companies.
Investors would do best to avoid this stock until the legal battle is resolved.
10 stocks we like better than Hims & Hers Health ›
Shares of Hims & Hers (NYSE: HIMS) stock sank 17% this week, according to data from S&P Global Market Intelligence. The telehealth platform is delivering huge revenue growth but is at risk of a legal battle with weight loss drugmakers. Shares of the stock are down 25% from all-time highs but are up 400% in the past five years due to the platform's fast growth.
Here's why the stock sank this week.
Fast growth but a looming lawsuit
In the second quarter of 2025, Hims & Hers' revenue grew 73% year over year to over $500 million, making it one of the fastest-growing companies in the world. This was driven by 30% growth in total subscribers to Hims & Hers products and 30% growth in spend per active subscriber. The company offers telehealth services for basic pharmaceuticals such as hair loss, sexual wellness, and weight loss drugs.
While the company is growing quickly and now generating a profit, Hims & Hers is facing a looming legal battle with Novo Nordisk. The innovator in weight loss drugs originally had a partnership with Hims & Hers but pulled out of the deal because of disagreements over Hims & Hers selling knockoffs of its weight loss drug formula. Hims & Hers was permitted to sell patented weight loss drugs while they were in shortage, but now that the shortage is over, it is breaking the law by selling patented drugs to customers at a discount.
Unsurprisingly, Hims & Hers is getting sued for this practice, which is a fast-growing part of its business. Investors are worried about the future impacts of this legal battle and how it could hurt Hims & Hers' future revenue growth and profitability.
Should you buy Hims & Hers stock?
Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in trailing revenue, up over 1,000% in the last five years. By far, it is the leading telehealth provider for drugs and medical treatments over the internet, making a ton of inroads in market share gains in the last few years.
If there were no legal battle looming, Hims & Hers would probably be a buy on this dip. However, we cannot ignore the potential legal ramifications and huge risk Hims & Hers management is putting on itself and shareholders by blatantly selling patented weight loss drugs on its website. This legal battle is not likely to end well. Don't buy the dip on Hims & Hers stock until its dispute with the weight loss drugmakers is resolved.
Do the experts think Hims & Hers Health is a buy right now?
The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list?
When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!*
Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!*
The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 4, 2025
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Why Hims & Hers Stock Sank This Week was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
e.l.f. Beauty, Inc. (ELF)'s Selling In Dollar General Because 'It's The Last One,' Says Jim Cramer
We recently published . e.l.f. Beauty, Inc. (NYSE:ELF) is one of the stocks Jim Cramer recently discussed. e.l.f. Beauty, Inc. (NYSE:ELF) is a firm that can't seem to catch a break. After struggling in a tough cosmetics market in 2024, the firm has continued to struggle in 2025 as investors fret about its ability to weather the inflationary storm from tariffs. e.l.f. Beauty, Inc. (NYSE:ELF)'s affordable cosmetics depend on its Chinese supply chain, making the tariff concerns self-explanatory. Cramer remarked on the firm selling cosmetics in Dollar General: '[On why ELF was selling its products in Dollar General] Because it's the last one. The shorts are telling me, not that I listen to the shorts, but the shorts are saying, what's after Dollar General? Is there anything after?' Copyright: antonioguillem / 123RF Stock Photo Here are his previous thoughts about e.l.f. Beauty, Inc. (NYSE:ELF): 'What the heck just happened to e.l.f. Beauty? I mean, the last time we got results from this low-cost cosmetics and skincare brand and the stock got eviscerated today, down nearly 10%. You know, we've long championed this one. It's been a great growth stock over the last few years, largely because it offers its customers quality merchandise at incredibly affordable prices. Unfortunately, it can charge low prices because it makes most of its goods in China, which means most of e.l.f.'s products are about to become more expensive. So last night, even though e.l.f. delivered a nice top and bottom line beat, management declined to issue a full year forecast because they really have no idea how the tariff situation's… going to play out. However, the limited guidance they gave did suggest that their margins are going to take a real hit… Maybe that's why things got, well, just awry.' While we acknowledge the potential of ELF as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
24 minutes ago
- Yahoo
GoDaddy Inc. (GDDY): Jim Cramer Is Surprised At Morgan Stanley's Report
We recently published . GoDaddy Inc. (NYSE:GDDY) is one of the stocks Jim Cramer recently discussed. GoDaddy Inc. (NYSE:GDDY) is an internet company that enables businesses to establish an online presence by setting up their websites. Its shares have lost 28% year-to-date after suffering from a steep 14% drop in February and an 11% dip in August. GoDaddy Inc. (NYSE:GDDY)'s shares fell in February after a fourth quarter revenue dip, while the August drop was driven by a weak EPS number, which beat analyst estimates by a rather modest three cents. Cramer discussed Morgan Stanley's decision to include GoDaddy Inc. (NYSE:GDDY) on its list of firms at risk from AI-led disruption, as he mentioned the firm's advertisement with actor Walton Goggins: '[On being included in Morgan Stanley's basket of companies at AI risk] Oh come on, Goggins, man!' Copyright: rawpixel / 123RF Stock Photo Here are Cramer's earlier thoughts about GoDaddy Inc. (NYSE:GDDY): 'As did by the way GoDaddy. . . I have GoDaddy on, I was kind of like, wow, that happened fast. While we acknowledge the potential of GDDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
24 minutes ago
- Yahoo
Amazon.com, Inc. (AMZN): Jim Cramer Maintains It Needs To Buy NVIDIA
We recently published . Inc. (NASDAQ:AMZN) is one of the stocks Jim Cramer recently discussed. Inc. (NASDAQ:AMZN) is struggling on the stock market lately as investors are worried about the growth prospects of its cloud computing division. The shares have gained a mere 1.4% over the past month, after they fell by 9.6% after the firm's second quarter earnings were accompanied by weak AWS growth. Cramer continues to maintain that Inc. (NASDAQ:AMZN) is struggling because it is focusing on its in-house AI chips instead of NVIDIA's AI GPUs: 'Think about what happened to Amazon, when they decided to go away from using all the NVIDIA that was possible. . . Copyright: veghsandor / 123RF Stock Photo Here are his previous thoughts about Inc. (NASDAQ:AMZN): 'We're in the era, this is what happens, The two big overhangs in this market had been Apple waiting for the sword of Damocles and Amazon, trading down because Amazon Web Services is viewed as a share donor. Both of those seem to have been forgotten. David, the forgotten negatives there has been replaced by we're dumping the big tariffs for now.' While we acknowledge the potential of AMZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
